Brief: British Columbia Reimburses Revestive® (Teduglutide For Injection) For The Treatment Of Short Bowel Syndrome
05/05/2026 13:32
May 5 (Reuters) - Takeda Pharmaceutical Co Ltd 4502.T: BRITISH COLUMBIA REIMBURSES REVESTIVE® (TEDUGLUTIDE FOR INJECTION) FOR THE TREATMENT OF SHORT BOWEL SYNDROME Source text: ID:nCNW9zCmwa Further company coverage: 4502.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Takeda Pharmaceutical
See all newsTakeda launches sleep disorder pill in the US after DEA clearance removes final hurdle (updated)
Brief: Takeda's Orzeyful Available In U.S. By Prescription To Treat Narcolepsy Type 1 In Adults
Takeda launches sleep disorder pill in the US after DEA clearance removes final hurdle
Takeda Pharmaceutical Company Limited reports results for the quarter ended September 30 - Earnings Summary
Table: Takeda Pharmaceutical Company Limited -6-MTH group results (IFRS)